These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34707005)

  • 1. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The influence of various myelosuppression degrees during neoadjuvant chemotherapy on the curative effect and prognosis of triple-negative breast cancer].
    Niu YD; Zhang YW; Zhu RJ; Chu T; Wang L; Wang S; Li YY; Dong Y
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(29):2290-2294. PubMed ID: 35927061
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical Significance of the Curative Effect after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer-Correlation to Prognosis].
    Haku E; Kojima Y; Sakamaki K; Kitajima M; Takishita M; Sakamoto N; Tazou M; Nakano M; Kuroda T; Yoshie R; Tsuruga T; Shimo A; Shimo A; Motoyoshi A; Kawamoto H; Fukuda M; Tsugawa K
    Gan To Kagaku Ryoho; 2020 Oct; 47(10):1449-1455. PubMed ID: 33130739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
    Pang J; Zhou H; Dong X; Wang S; Xiao Z
    Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
    JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].
    Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034
    [No Abstract]   [Full Text] [Related]  

  • 12. Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.
    Liu P; Jiang Y; Zheng X; Pan B; Xiang H; Zheng M
    Pathol Oncol Res; 2022; 28():1610294. PubMed ID: 35570842
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer.
    Lou C; Jin F; Zhao Q; Qi H
    Am J Transl Res; 2022; 14(5):3240-3246. PubMed ID: 35702128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
    Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer.
    Liu J; Shi Z; Bai Y; Liu L; Cheng K
    Cancer Manag Res; 2019; 11():4471-4480. PubMed ID: 31191009
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer.
    Yang G; Liu P; Zheng L; Zeng J
    Front Surg; 2022; 9():1004687. PubMed ID: 36406359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
    Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
    Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Shi Y; Lu H; Zhang Y
    Breast Cancer Res Treat; 2024 Jul; 206(2):387-395. PubMed ID: 38658447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.